Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Concurrent whole brain radiotherapy and bortezomib for brain metastasis

Lao, CD and Friedman, J and Tsien, CI and Normolle, DP and Chapman, C and Cao, Y and Lee, O and Schipper, M and Van Poznak, C and Hamstra, D and Lawrence, T and Hayman, J and Redman, BG (2013) Concurrent whole brain radiotherapy and bortezomib for brain metastasis. Radiation Oncology, 8 (1).

Published Version
Available under License : See the attached license file.

Download (367kB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)


Background: Survival of patients with brain metastasis particularly from historically more radio-resistant malignancies remains dismal. A phase I study of concurrent bortezomib and whole brain radiotherapy was conducted to determine the tolerance and safety of this approach in patients with previously untreated brain metastasis.Methods: A phase I dose escalation study evaluated the safety of bortezomib (0.9, 1.1, 1.3, 1.5, and 1.7 mg/m2) given on days 1, 4, 8 and 11 of whole brain radiotherapy. Patients with confirmed brain metastasis were recruited for participation. The primary endpoint was the dose-limiting toxicity, defined as any ≥ grade 3 non-hematologic toxicity or grade ≥ 4 hematologic toxicity from the start of treatment to one month post irradiation. Time-to-Event Continual Reassessment Method (TITE-CRM) was used to determine dose escalation. A companion study of brain diffusion tensor imaging MRI was conducted on a subset of patients to assess changes in the brain that might predict delayed cognitive effects.Results: Twenty-four patients were recruited and completed the planned therapy. Patients with melanoma accounted for 83% of all participants. The bortezomib dose was escalated as planned to the highest dose of 1.7 mg/m2/dose. No grade 4/5 toxicities related to treatment were observed. Two patients had grade 3 dose-limiting toxicities (hyponatremia and encephalopathy). A partial or minor response was observed in 38% of patients. Bortezomib showed greater demyelination in hippocampus-associated white matter structures on MRI one month after radiotherapy compared to patients not treated with bortezomib (increase in radial diffusivity +16.8% versus 4.8%; p = 0.0023).Conclusions: Concurrent bortezomib and whole brain irradiation for brain metastasis is well tolerated at one month follow-up, but MRI changes that have been shown to predict delayed cognitive function can be detected within one month of treatment. © 2013 Lao et al.; licensee BioMed Central Ltd.


Social Networking:
Share |


Item Type: Article
Status: Published
CreatorsEmailPitt UsernameORCID
Lao, CD
Friedman, J
Tsien, CI
Normolle, DPdpn7@pitt.eduDPN70000-0001-8675-5014
Chapman, C
Cao, Y
Lee, O
Schipper, M
Van Poznak, C
Hamstra, D
Lawrence, T
Hayman, J
Redman, BG
Date: 21 August 2013
Date Type: Publication
Journal or Publication Title: Radiation Oncology
Volume: 8
Number: 1
DOI or Unique Handle: 10.1186/1748-717x-8-204
Schools and Programs: School of Public Health > Biostatistics
Refereed: Yes
Date Deposited: 02 Dec 2016 14:59
Last Modified: 04 Jan 2023 11:56


Monthly Views for the past 3 years

Plum Analytics

Actions (login required)

View Item View Item